Derivation of Biomonitoring Equivalents for cyfluthrin

Hays, Sean M., Aylward, Lesa L., Gagne, Michelle and Krishnan, Kannan (2009) Derivation of Biomonitoring Equivalents for cyfluthrin. Regulatory Toxicology and Pharmacology, 55 3: 268-275. doi:10.1016/j.yrtph.2009.09.002


Author Hays, Sean M.
Aylward, Lesa L.
Gagne, Michelle
Krishnan, Kannan
Title Derivation of Biomonitoring Equivalents for cyfluthrin
Journal name Regulatory Toxicology and Pharmacology   Check publisher's open access policy
ISSN 0273-2300
1096-0295
Publication date 2009-12
Sub-type Article (original research)
DOI 10.1016/j.yrtph.2009.09.002
Open Access Status Not yet assessed
Volume 55
Issue 3
Start page 268
End page 275
Total pages 8
Place of publication Maryland Heights, MO, United States
Publisher Academic Press
Language eng
Abstract Recent efforts worldwide have resulted in a growing database of measured concentrations of chemicals in blood and urine samples taken from the general population. However, few tools exist to assist in the interpretation of the measured values in a health risk context. Biomonitoring Equivalents (BEs) are defined as the concentration or range of concentrations of a chemical or its metabolite in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guideline, and are derived by integrating available data on pharmacokinetics with existing chemical risk assessments. This study reviews available health-based exposure guidance values for cyfluthrin from Health Canada, the United States Environmental Protection Agency (USEPA), and the World Health Organization/Food and Agriculture Organization. BE values corresponding to the oral reference dose (RfD), or acceptable daily intake (ADI) estimates from these agencies were derived based on data on excretion fractions of the urinary metabolite 4-fluoro-3-phenoxybenzoic acid (FPBA), which is a metabolite specific to cyfluthrin. These values may be used as screening tools for evaluation of biomonitoring data for cyfluthrin as the metabolite FPBA in the context of existing risk assessments and for prioritization of the potential need for additional risk assessment efforts for cyfluthrin relative to other chemicals.
Keyword Biomonitoring
Biomonitoring Equivalents
Pharmacokinetics
Risk assessment
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: National Research Centre for Environmental Toxicology Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 24 Mar 2016, 11:23:37 EST by System User on behalf of Learning and Research Services (UQ Library)